Peripheral blood reverse transcription PCR assay for prostate stem cell antigen correlates with androgen-independent progression in advanced prostate cancer

International Journal of Cancer

Volumn 131, Issue 4, 2012, Pages 902-910

  Zhao, Zhigang ^a   Zeng, Guohua ^a   Ma, Wenjing ^a   Ou, Lili ^a   Liang, Yeping ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

prognosis; prostate cancer; prostate stem cell antigen; reverse transcription polymerase chain reaction

Indexed keywords

ANTIANDROGEN; COMPLEMENTARY DNA; MESSENGER RNA; PROSTATE STEM CELL ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ANDROGEN INDEPENDENT PROGRESSION; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER REGRESSION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM;

ANDROGEN ANTAGONISTS; ANTIGENS, NEOPLASM; BASE SEQUENCE; COHORT STUDIES; DISEASE PROGRESSION; DNA PRIMERS; GPI-LINKED PROTEINS; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84862565209     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26459     Document Type: Article

References (27)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Dai B, Ye DW, Kong YY, Shen YJ, Wang BH,. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels. Asian J Androl 2008; 10: 325-31. (Pubitemid 351337998)
3. Peyromaure M, Debre B, Mao K, Zhang G, Wang Y,. Management of prostate cancer in China: a multicenter report of 6 institutions. J Urol 2005; 174: 1794-97. (Pubitemid 41546942)
4. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, David E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON,. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998; 95: 1735-40. (Pubitemid 28103463)
5. Antica M, Wu L, Scollay R,. Stem cell antigen 2 expression in adult and developing mice. Immunol Lett 1997; 55: 47-51. (Pubitemid 27117494)
6. Classon BJ, Coverdale L,. Mouse stem cell antigen Sca-2 is a member of the Ly-6 family of cell surface proteins. Proc Natl Acad Sci USA 1994; 91: 5296-300. (Pubitemid 24174313)
7. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE,. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000; 19: 1288-96. (Pubitemid 30160621)
8. Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said JW, Reiter RE,. Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol 2004; 171: 1117-21. (Pubitemid 38327539)
9. Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE,. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 2005; 11: 2591-96. (Pubitemid 40569458)
10. Dannull J, Diener PA, Prikler L, Fürstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M,. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000; 60: 5522-8.
11. Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH,. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 1994; 11: 153-62. (Pubitemid 24333390)
12. Hara N, Kasahara T, Kawasaki T, Bilim V, Obara K, Takahashi K, Tomita Y,. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin Cancer Res 2002; 8: 1794-99. (Pubitemid 34633737)
13. Joung JY, Yang SO, Jeong IG, Han KS, Seo HK, Chung J, Park WS, Lee KH,. Reverse transcriptase-polymerase chain reaction and immunohistochemical studies for detection of prostate stem cell antigen expression in prostate cancer: potential value in molecular staging of prostate cancer. Int J Urol 2007; 14: 635-43. (Pubitemid 47084106)
14. Joung JY, Cho KS, Kim JE, Seo HK, Chung J, Park WS, Choi MK, Lee KH,. Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high-risk prostate cancer. J Surg Oncol 2010; 101: 145-8.
15. Greene FL,. AJCC cancer staging manual. New York: Springer-Verlag, 2002. 309.
16. Gleason DF, Mellinger GT,. The Veterans Administrative Cooperative Urologic Research Group. Histologic grading and clinical staging of prostatic carcinoma. In:, Tannenbaum M, ed. Urologic pathology: the prostate. Philadelphia, Lea & Febiger, 1998. pp. 171-98.
17. Smith DS, Catalona WJ, Herschman JD,. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996; 276: 1309-15. (Pubitemid 26346930)
18. Morote J, Trilla E, Esquena S, Abascal JM, Reventos J,. Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Cancer 2004; 108: 877-81. (Pubitemid 38112617)
19. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK,. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 2008; 112: 1247-53. (Pubitemid 351429739)
20. Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M,. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2008; 26: 842-7. (Pubitemid 351398074)
21. Ghossein RA, Bhattacharya S,. Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. Eur J Cancer 2000; 36: 1681-94. (Pubitemid 30616372)
22. Raj GV, Moreno JG, Gomella LG,. Utilization of polymerase chain reaction technology in the detection of solid tumors. Cancer 1998; 82: 1419-42. (Pubitemid 28164986)
23. Benain EA, Pace CM, Lam PO, Roehrborn CG,. Nadir prostate specific antigen as a redictor of progression to androgen-independent prostate cancer. Urology 2002; 59: 73-8. (Pubitemid 34059310)
24. Benaim EA, Pace CM, Roehrborn CG,. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urol 2002; 42: 12-7. (Pubitemid 35339640)
25. Amato RJ, Teh BS, Henary H, Khan M, Saxena S,. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate. Urol Oncol 2009; 27: 165-9.
26. Zhao Z, Shen W,. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma. Prostate 2005; 65: 299-305.
27. Zhao Z, Ma W, Zeng G, Qi D, Ou L, Liang Y,. Small interference RNA-mediated silencing of prostate stem cell antigen attenuates growth, reduces migration and invasion of human prostate cancer PC-3M cells. Urol Oncol, 2011. doi: org/10.1016/j.urolonc.2011.02.004.